BioNTech SE (NASDAQ:BNTX - Get Free Report) was the target of some unusual options trading activity on Monday. Traders bought 1,989 call options on the company. This represents an increase of approximately 31% compared to the average volume of 1,519 call options.
BioNTech Stock Up 0.7 %
Shares of BNTX traded up $0.63 during mid-day trading on Monday, reaching $93.35. The company's stock had a trading volume of 1,096,207 shares, compared to its average volume of 659,535. BioNTech has a 1 year low of $85.21 and a 1 year high of $125.83. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The company has a market cap of $22.19 billion, a price-to-earnings ratio of 22.66 and a beta of 0.25. The business has a fifty day moving average of $90.54 and a 200 day moving average of $95.99.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts' consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. As a group, analysts forecast that BioNTech will post -1.74 earnings per share for the current fiscal year.
Institutional Trading of BioNTech
A number of institutional investors have recently bought and sold shares of BNTX. Baillie Gifford & Co. grew its stake in shares of BioNTech by 1.0% in the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company's stock valued at $917,056,000 after buying an additional 86,343 shares in the last quarter. Primecap Management Co. CA boosted its holdings in BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company's stock worth $502,735,000 after purchasing an additional 131,490 shares in the last quarter. Harding Loevner LP acquired a new position in BioNTech during the fourth quarter worth $410,984,000. Flossbach Von Storch AG raised its holdings in BioNTech by 1.0% during the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company's stock valued at $374,526,000 after buying an additional 35,445 shares in the last quarter. Finally, Capital World Investors lifted its position in shares of BioNTech by 1.5% in the fourth quarter. Capital World Investors now owns 938,747 shares of the company's stock worth $99,075,000 after buying an additional 14,027 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently commented on BNTX shares. BMO Capital Markets dropped their price objective on BioNTech from $127.00 to $123.00 and set an "outperform" rating on the stock in a research note on Thursday, March 21st. UBS Group lowered their price objective on shares of BioNTech from $110.00 to $101.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 27th. HC Wainwright reissued a "buy" rating and set a $107.00 target price on shares of BioNTech in a research note on Wednesday, April 17th. The Goldman Sachs Group decreased their price target on shares of BioNTech from $113.00 to $100.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. cut their price objective on BioNTech from $99.00 to $90.00 and set an "underweight" rating for the company in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $120.40.
Read Our Latest Stock Analysis on BNTX
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
